Company Filing History:
Years Active: 2007
Title: Inventor Spotlight: Sarah Margaret Kelly - Innovating in Neuropharmacology
Introduction: Sarah Margaret Kelly, a pioneering inventor based in Harlow, GB, is making waves in the field of neuropharmacology with her groundbreaking patent on Imidazo-pyridine derivatives as ligands for GABA receptors.
Latest Patents: Sarah holds one patent for a class of 8-fluoro-3-phenylimidazo[1,2-α]pyridine derivatives that serve as selective ligands for GABA receptors. These derivatives show high affinity for the α2, α3, and/or α5 subunits, making them highly beneficial in the treatment and prevention of various central nervous system conditions including anxiety, convulsions, and cognitive disorders.
Career Highlights: Sarah is a valued member of the research and development team at Merck Sharp & Dohme Corporation, where she has been instrumental in driving innovation in neuropharmacology. Her dedication to her work and passion for advancing the field have earned her recognition among her peers.
Collaborations: Working closely with esteemed colleagues such as Simon Charles Goodacre and David James Hallett, Sarah has been able to leverage collective expertise and insights to further refine her inventions and push the boundaries of neuropharmacological research.
Conclusion: Sarah Margaret Kelly's inventive spirit and commitment to advancing neuropharmacology are evident in her pioneering work on Imidazo-pyridine derivatives. Her contributions to the field hold tremendous promise for the future of central nervous system treatments, and her collaborations with esteemed professionals underscore the power of teamwork in driving innovation forward.